U.S. CDMRP – Breast Cancer Research Program
Event details
| Date | 13.06.2025 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2025 Breast Cancer Research Program (BCRP) Awards. Several award programs are available:
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline: 13 June 2025, 5:00 p.m. Eastern time
Full Application Deadline: 27 June 2025, 5:00 p.m. Eastern time
Further information:
- The Breakthrough Awards supports promising research that has high potential to lead to or make breakthroughs in breast cancer. The Breakthrough Award is structured with three different funding levels. Each level has a defined research scope :
- Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome.
- Funding Level 2: Research that is already supported by substantial preliminary or published data in breast cancer and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
- Funding Level 2: Population Science and Prevention Studies: The studies should focus on the analysis of human data and biospecimens. Research should be already supported by substantial preliminary or published data in breast cancer and strongly validate clinical translation in a well-defined context within the breast cancer landscape. With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance.
- Funding Level 3: Advanced translational studies. Where relevant, the proposed research must be supported by proof of the availability of, and access to, necessary data, human samples, cohort(s), and/or critical reagents. If the proposed research will ultimately require U.S. Food and Drug Administration (FDA) or an equivalent international regulatory agency involvement, the project must be supported by demonstrated availability of, and access to, clinical reagents (e.g., therapeutics) and subject population(s). A realistic timeline for near-term clinical research, as defined elsewhere in this program announcement, must be stated. Small-scale clinical trials (e.g., first-in-human, phase 1/1b) may be appropriate.
- The Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Patients’ contributions of tissue, serum, and other biologic specimens and their data are invaluable to saving lives. The BCRP has created this award mechanism to help ensure that science values those contributions with research that maximizes their impact.
- The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.
- Breakthrough 1: $450K - $900K
- Breakthrough 2: $1.2M - $2.4M
- Breakthrough 3: $4M - $5M
- Clinical Research Extension: $5M - $6M
- Era of Hope: max. $3.5M
- Breakthrough 1: 3 years
- Breakthrough 2: 4 years
- Breakthrough 3: 4 years
- Clinical Research Extension: 4 years
- Era of Hope: 4 years
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline: 13 June 2025, 5:00 p.m. Eastern time
Full Application Deadline: 27 June 2025, 5:00 p.m. Eastern time
Further information:
- To find the full program announcements and to start your pre-application see here
- A useful summary of each call can be found here
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
- Grants.gov Funding Opportunity Numbers:
- Breakthrough 1: HT942525BCRPBTA12
- Breakthrough 2: HT942525BCRPBTA12
- Breakthrough 3: HT942525BCRPBTA3
- Clinical Research Extension: HT942525BCRPCREA
- Era of Hope: HT942525BCRPEOHS
Practical information
- General public
- Free
Contact
- research@epfl.ch